...
search icon
onc-img

BeiGene, Ltd., Common Stock

ONC

NSQ

$230.98

+$2.84

(1.24%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$24.82B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
0
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.49
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$129.96 L
$287.88 H
$230.98

About BeiGene, Ltd., Common Stock

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameONCSectorS&P500
1-Week Return10.88%0.44%0.24%
1-Month Return-12.86%-7.69%-7.32%
3-Month Return9.95%-3.35%-12.05%
6-Month Return8.75%-11.09%-9.73%
1-Year Return75.17%-2.13%5.05%
3-Year Return34.18%-1.18%20.03%
5-Year Return46.72%34.44%83.31%
10-Year Return715.61%84.87%153.54%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue308.87M1.18B1.42B2.46B3.81B[{"date":"2020-12-31","value":8.11,"profit":true},{"date":"2021-12-31","value":30.87,"profit":true},{"date":"2022-12-31","value":37.16,"profit":true},{"date":"2023-12-31","value":64.53,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue1.37B1.62B1.93B379.92M594.09M[{"date":"2020-12-31","value":70.86,"profit":true},{"date":"2021-12-31","value":84.28,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":19.72,"profit":true},{"date":"2024-12-31","value":30.83,"profit":true}]
Gross Profit(1.06B)(447.86M)(511.06M)2.08B3.22B[{"date":"2020-12-31","value":-32.85,"profit":false},{"date":"2021-12-31","value":-13.93,"profit":false},{"date":"2022-12-31","value":-15.89,"profit":false},{"date":"2023-12-31","value":64.64,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin(342.10%)(38.07%)(36.09%)84.55%84.41%[{"date":"2020-12-31","value":-404.62,"profit":false},{"date":"2021-12-31","value":-45.03,"profit":false},{"date":"2022-12-31","value":-42.69,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":99.83,"profit":true}]
Operating Expenses601.02M990.87M1.28B3.29B3.78B[{"date":"2020-12-31","value":15.88,"profit":true},{"date":"2021-12-31","value":26.18,"profit":true},{"date":"2022-12-31","value":33.79,"profit":true},{"date":"2023-12-31","value":86.85,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(1.66B)(1.44B)(1.79B)(1.21B)(568.20M)[{"date":"2020-12-31","value":-165768200000,"profit":false},{"date":"2021-12-31","value":-143873500000,"profit":false},{"date":"2022-12-31","value":-178966500000,"profit":false},{"date":"2023-12-31","value":-120773600000,"profit":false},{"date":"2024-12-31","value":-56819900000,"profit":false}]
Total Non-Operating Income/Expense41.49M(15.61M)(118.89M)455.91M83.03M[{"date":"2020-12-31","value":9.1,"profit":true},{"date":"2021-12-31","value":-3.42,"profit":false},{"date":"2022-12-31","value":-26.08,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":18.21,"profit":true}]
Pre-Tax Income(1.62B)(1.44B)(1.96B)(825.84M)(533.00M)[{"date":"2020-12-31","value":-161819400000,"profit":false},{"date":"2021-12-31","value":-143858800000,"profit":false},{"date":"2022-12-31","value":-196103700000,"profit":false},{"date":"2023-12-31","value":-82583600000,"profit":false},{"date":"2024-12-31","value":-53300100000,"profit":false}]
Income Taxes(17.67M)(25.23M)42.78M55.87M111.78M[{"date":"2020-12-31","value":-15.81,"profit":false},{"date":"2021-12-31","value":-22.57,"profit":false},{"date":"2022-12-31","value":38.27,"profit":true},{"date":"2023-12-31","value":49.98,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(1.60B)(1.41B)(2.00B)(881.71M)(644.79M)[{"date":"2020-12-31","value":-160052300000,"profit":false},{"date":"2021-12-31","value":-141335400000,"profit":false},{"date":"2022-12-31","value":-200381500000,"profit":false},{"date":"2023-12-31","value":-88170800000,"profit":false},{"date":"2024-12-31","value":-64478600000,"profit":false}]
Income From Continuous Operations(1.63B)(1.46B)(2.00B)(881.71M)(644.79M)[{"date":"2020-12-31","value":-162859100000,"profit":false},{"date":"2021-12-31","value":-145781600000,"profit":false},{"date":"2022-12-31","value":-200381500000,"profit":false},{"date":"2023-12-31","value":-88170800000,"profit":false},{"date":"2024-12-31","value":-64478600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(1.60B)(1.41B)(2.00B)(881.71M)(644.79M)[{"date":"2020-12-31","value":-160052300000,"profit":false},{"date":"2021-12-31","value":-141335400000,"profit":false},{"date":"2022-12-31","value":-200381500000,"profit":false},{"date":"2023-12-31","value":-88170800000,"profit":false},{"date":"2024-12-31","value":-64478600000,"profit":false}]
EPS (Diluted)(18.99)(15.17)(19.48)(8.45)(6.14)[{"date":"2020-12-31","value":-1898.9,"profit":false},{"date":"2021-12-31","value":-1516.63,"profit":false},{"date":"2022-12-31","value":-1947.67,"profit":false},{"date":"2023-12-31","value":-845.33,"profit":false},{"date":"2024-12-31","value":-614,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ONC
Cash Ratio 1.19
Current Ratio 1.80
Quick Ratio 1.58

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ONC
ROA (LTM) -6.07%
ROE (LTM) -18.77%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ONC
Debt Ratio Lower is generally better. Negative is bad. 0.44
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.56

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ONC
Trailing PE NM
Forward PE 370.37
P/S (TTM) 7.05
P/B 7.47
Price/FCF NM
EV/R 6.64
EV/Ebitda NM

FAQs

What is BeiGene, Ltd. share price today?

BeiGene, Ltd. (ONC) share price today is $230.98

Can Indians buy BeiGene, Ltd. shares?

Yes, Indians can buy shares of BeiGene, Ltd. (ONC) on Vested. To buy BeiGene, Ltd. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ONC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of BeiGene, Ltd. be purchased?

Yes, you can purchase fractional shares of BeiGene, Ltd. (ONC) via the Vested app. You can start investing in BeiGene, Ltd. (ONC) with a minimum investment of $1.

How to invest in BeiGene, Ltd. shares from India?

You can invest in shares of BeiGene, Ltd. (ONC) via Vested in three simple steps:

  • Click on Sign Up or Invest in ONC stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in BeiGene, Ltd. shares
What is BeiGene, Ltd. 52-week high and low stock price?

The 52-week high price of BeiGene, Ltd. (ONC) is $287.88. The 52-week low price of BeiGene, Ltd. (ONC) is $129.96.

What is BeiGene, Ltd. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of BeiGene, Ltd. (ONC) is 7.47

What is the Market Cap of BeiGene, Ltd.?

The market capitalization of BeiGene, Ltd. (ONC) is $24.82B

What is BeiGene, Ltd.’s stock symbol?

The stock symbol (or ticker) of BeiGene, Ltd. is ONC

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top